Tomoko Iehara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomoko Iehara has a total of 270 co-authors. Here are the top co-authors by number of shared publications:
Hajime Hosoi
28 shared publications- Shigeki Yagyu
Department of Research and Development, A-SEEDS Co., Ltd., Matsumoto, Nagano, Japan; Center for Advanced Research of Gene and Cell Therapy, Innovative Research & Liaison Organization, Shinshu University, Matsumoto, Nagano, Japan
26 shared publications - Ken Kikuchi
Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan
21 shared publications Kunihiko Tsuchiya
Department of Pediatrics Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
19 shared publicationsMitsuru Miyachi
Department of Pediatrics Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
19 shared publicationsHideki Yoshida
Department of Pediatrics Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
17 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S1 shows Map of the SALL4 promoter (pSALL4) region in human and structure of pSALL4-OAd.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S1 shows Map of the SALL4 promoter (pSALL4) region in human and structure of pSALL4-OAd.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Table S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Table S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S4 shows Isotype control staining
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S4 shows Isotype control staining
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
SALL4 expression in Rhabdoid Tumors in the TARGET database
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
SALL4 expression in Rhabdoid Tumors in the TARGET database
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S3 shows expression of CLDN6 and USP44 mRNA in RT cell lines
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S3 shows expression of CLDN6 and USP44 mRNA in RT cell lines
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Data from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.
- Open Access
- 16 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2275
High PEEP Increases Airway Dead Space and Decreases Alveolar Ventilation: A New Technique for Volumetric Capnography
Background/Objectives: Identifying the optimal positive end-expiratory pressure (PEEP) is a major challenge in implementing strategies to prevent ventilator-induced lung injury in newborns. In this study, we assessed the validity of volumetric capnography based on the neonatal patient monitor (Vcap,PM) technique and investigated the impact of PEEP on newborns. Methods: Analysis 1 evaluated the validity of the Vcap,PM technique with data from pediatric patients receiving invasive respiratory support. Linear regression and Bland–Altman analyses were performed on Vcap,PM and HAMILTON-C1 data. Analysis 2 evaluated the impact of PEEP on newborns. The PEEP level was increased from mild to high (the incremental phase) and then decreased from high to mild (the decremental phase) while performing the Vcap,PM technique on term and preterm infants. Results: Analysis 1 included 31 children (age, 9 [interquartile range (IQR), 0–36] months; weight, 6.0 [IQR, 3.8–10.5] kg). Regression and Bland–Altman analyses demonstrated the accuracy of Vcap,PM. Analysis 2 included 28 term (mean gestational age, 38 [IQR, 38–40] weeks; weight, 2924 [IQR, 2725–3109] g) and 21 preterm (mean gestational age, 33 [IQR, 31–34] weeks; weight, 1918 [IQR, 1356–2186] g) newborns. Despite no difference in tidal volume, high PEEP significantly increased airway dead space and decreased alveolar tidal volume compared to mild PEEP in each phase in term and preterm neonates. Conclusions: High PEEP induced airway dilation in newborns, as determined using a novel Vcap technique. This technique, which requires no special equipment, has the potential for wider clinical application in neonatal care.
- 16 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2275
Open AccessHigh PEEP Increases Airway Dead Space and Decreases Alveolar Ventilation: A New Technique for Volumetric Capnography
Background/Objectives: Identifying the optimal positive end-expiratory pressure (PEEP) is a major challenge in implementing strategies to prevent ventilator-induced lung injury in newborns. In this study, we assessed the validity of volumetric capnography based on the neonatal patient monitor (Vcap,PM) technique and investigated the impact of PEEP on newborns. Methods: Analysis 1 evaluated the validity of the Vcap,PM technique with data from pediatric patients receiving invasive respiratory support. Linear regression and Bland–Altman analyses were performed on Vcap,PM and HAMILTON-C1 data. Analysis 2 evaluated the impact of PEEP on newborns. The PEEP level was increased from mild to high (the incremental phase) and then decreased from high to mild (the decremental phase) while performing the Vcap,PM technique on term and preterm infants. Results: Analysis 1 included 31 children (age, 9 [interquartile range (IQR), 0–36] months; weight, 6.0 [IQR, 3.8–10.5] kg). Regression and Bland–Altman analyses demonstrated the accuracy of Vcap,PM. Analysis 2 included 28 term (mean gestational age, 38 [IQR, 38–40] weeks; weight, 2924 [IQR, 2725–3109] g) and 21 preterm (mean gestational age, 33 [IQR, 31–34] weeks; weight, 1918 [IQR, 1356–2186] g) newborns. Despite no difference in tidal volume, high PEEP significantly increased airway dead space and decreased alveolar tidal volume compared to mild PEEP in each phase in term and preterm neonates. Conclusions: High PEEP induced airway dilation in newborns, as determined using a novel Vcap technique. This technique, which requires no special equipment, has the potential for wider clinical application in neonatal care.
- Open Access
- 15 August 2025
- Published by MDPI AG in Preprints.org
High PEEP Increases Airway Dead Space and Decreases Alveolar Ventilation: A New Technique for Volumetric Capnography
Background/Objectives: Identifying the optimal positive end-expiratory pressure (PEEP) is a major challenge in implementing strategies to prevent ventilator-induced lung injury in newborns. In this study, we assessed the validity of volumetric capnography based on the neonatal patient monitor (Vcap,PM) technique and investigated the impact of PEEP on newborns. Methods: Analysis 1 evaluated the validity of Vcap,PM technique with data from pediatric patients receiving invasive respiratory support. Linear regression and Bland–Altman analyses were performed on Vcap,PM and HAMILTON-C1 data. Analysis 2 evaluated the impact of PEEP on newborns. The PEEP level was increased from mild to high (the incremental phase) and then decreased from high to mild (the decremental phase) while performing the Vcap,PM technique on term and preterm infants. Results: Analysis 1 included 31 children (age, 9 [interquartile range (IQR), 0–36] months; weight, 6.0 [IQR, 3.8–10.5] kg). Regression and Bland–Altman analyses demonstrated the accuracy of Vcap,PM. Analysis 2 included 28 term (mean gestational age, 38 [IQR, 38–40] weeks; weight, 2,924 [IQR, 2,725–3,109] g) and 21 preterm (mean gestational age, 33 [IQR, 31–34] weeks; weight, 1,918 [IQR, 1,356–2,186] g) newborns. Despite no difference in tidal volume, high PEEP significantly increased airway dead space and decreased alveolar tidal volume compared to mild PEEP in each phase in term and preterm neonates. Conclusions: High PEEP induced airway dilation in newborns, as determined using a novel Vcap technique. This technique, which requires no special equipment, has the potential for wider clinical application in neonatal care.
- 15 August 2025
- Published by MDPI AG in Preprints.org
Open AccessHigh PEEP Increases Airway Dead Space and Decreases Alveolar Ventilation: A New Technique for Volumetric Capnography
Background/Objectives: Identifying the optimal positive end-expiratory pressure (PEEP) is a major challenge in implementing strategies to prevent ventilator-induced lung injury in newborns. In this study, we assessed the validity of volumetric capnography based on the neonatal patient monitor (Vcap,PM) technique and investigated the impact of PEEP on newborns. Methods: Analysis 1 evaluated the validity of Vcap,PM technique with data from pediatric patients receiving invasive respiratory support. Linear regression and Bland–Altman analyses were performed on Vcap,PM and HAMILTON-C1 data. Analysis 2 evaluated the impact of PEEP on newborns. The PEEP level was increased from mild to high (the incremental phase) and then decreased from high to mild (the decremental phase) while performing the Vcap,PM technique on term and preterm infants. Results: Analysis 1 included 31 children (age, 9 [interquartile range (IQR), 0–36] months; weight, 6.0 [IQR, 3.8–10.5] kg). Regression and Bland–Altman analyses demonstrated the accuracy of Vcap,PM. Analysis 2 included 28 term (mean gestational age, 38 [IQR, 38–40] weeks; weight, 2,924 [IQR, 2,725–3,109] g) and 21 preterm (mean gestational age, 33 [IQR, 31–34] weeks; weight, 1,918 [IQR, 1,356–2,186] g) newborns. Despite no difference in tidal volume, high PEEP significantly increased airway dead space and decreased alveolar tidal volume compared to mild PEEP in each phase in term and preterm neonates. Conclusions: High PEEP induced airway dilation in newborns, as determined using a novel Vcap technique. This technique, which requires no special equipment, has the potential for wider clinical application in neonatal care.
- 19 May 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (10) , 1527-1536
A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.
- 19 May 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (10) , 1527-1536
A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.
- Open Access
- 9 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (8) , e31770
Treatment of Intermediate‐Risk Hepatoblastoma Using a Combined Cisplatin and Doxorubicin (PLADO) Regimen and Optimized Surgical Resection
Background: Complete resection of the primary tumor is critical for the survival of children with hepatoblastomas (HBs). This prospective clinical study aimed to clarify the outcome of a chemotherapy regimen comprising cisplatin and doxorubicin (PLADO) followed by definitive surgery conducted at the appropriate time in patients with intermediate‐risk HB.Methods: Intermediate‐risk HB was defined as patients without evidence of metastatic disease who met any of the following criteria: age ≥3 years; PRETEXT IV disease; presence of more than one PRETEXT annotation factor. The study protocol consisted of four preoperative and two postoperative courses of PLADO. The appropriate surgeries were conducted at optimized timings via real‐time central surgical reviews.Results: The 3‐year progression‐free and overall survivals of the 33 intermediate‐risk patients included were 78.7% and 87.9%, respectively. Preoperative PLADO resulted in a partial response in 83.9% of the patients. Microscopic complete resection was ultimately obtained in 31 (94%) patients. No patient required more than six preoperative courses before surgery or liver transplantation (LTx). Two patients never had surgery due to tumor progression.Conclusions: The outcome for patients with intermediate‐risk HB was satisfactory. PLADO, combined with surgery (including LTx) conducted at the optimal time, appeared to cure most patients in this study.
- 9 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (8) , e31770
Open AccessTreatment of Intermediate‐Risk Hepatoblastoma Using a Combined Cisplatin and Doxorubicin (PLADO) Regimen and Optimized Surgical Resection
Background: Complete resection of the primary tumor is critical for the survival of children with hepatoblastomas (HBs). This prospective clinical study aimed to clarify the outcome of a chemotherapy regimen comprising cisplatin and doxorubicin (PLADO) followed by definitive surgery conducted at the appropriate time in patients with intermediate‐risk HB.Methods: Intermediate‐risk HB was defined as patients without evidence of metastatic disease who met any of the following criteria: age ≥3 years; PRETEXT IV disease; presence of more than one PRETEXT annotation factor. The study protocol consisted of four preoperative and two postoperative courses of PLADO. The appropriate surgeries were conducted at optimized timings via real‐time central surgical reviews.Results: The 3‐year progression‐free and overall survivals of the 33 intermediate‐risk patients included were 78.7% and 87.9%, respectively. Preoperative PLADO resulted in a partial response in 83.9% of the patients. Microscopic complete resection was ultimately obtained in 31 (94%) patients. No patient required more than six preoperative courses before surgery or liver transplantation (LTx). Two patients never had surgery due to tumor progression.Conclusions: The outcome for patients with intermediate‐risk HB was satisfactory. PLADO, combined with surgery (including LTx) conducted at the optimal time, appeared to cure most patients in this study.